Fujimoto Naohiro, Shiota Masaki, Tomisaki Ikko, Minato Akinori
Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Clin Genitourin Cancer. 2017 Jun;15(3):337-342. doi: 10.1016/j.clgc.2017.01.006. Epub 2017 Jan 18.
Among patients with prostate cancer, the prognosis after androgen deprivation therapy differs significantly among individuals and among races; however, the reasons underlying these differences are poorly understood. Several single nucleotide polymorphisms in genes associated with prostate cancer progression or castration resistance might serve as the host factor that influences prognosis and, thus, accounts for these individual and racial gaps in treatment outcomes. Accordingly, single nucleotide polymorphisms associated with treatment outcomes could be used as predictive and/or prognostic biomarkers for patient stratification and to identify personalized treatment and follow-up protocols. The present review has summarized the genetic polymorphisms that have been reported to associate with androgen deprivation therapy outcomes among patients with prostate cancer and compared the allele frequencies among different ethnic groups.
在前列腺癌患者中，雄激素剥夺治疗后的预后在个体之间和种族之间存在显著差异；然而，这些差异背后的原因却知之甚少。与前列腺癌进展或去势抵抗相关的基因中的几个单核苷酸多态性可能作为影响预后的宿主因素，从而解释了治疗结果中的这些个体和种族差异。因此，与治疗结果相关的单核苷酸多态性可作为预测和/或预后生物标志物，用于患者分层，并确定个性化的治疗和随访方案。本综述总结了已报道的与前列腺癌患者雄激素剥夺治疗结果相关的基因多态性，并比较了不同种族群体之间的等位基因频率。
